Bay State Times
SEE OTHER BRANDS

The latest news from Massachusetts

Bay State Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Bay State Times.

Press releases published on May 8, 2025

Berman Tabacco Announces Investigation of Compass Diversified Holdings (CODI) Concerning Accounting Practices

Berman Tabacco Announces Investigation of Compass Diversified Holdings (CODI) Concerning Accounting Practices

BOSTON, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Berman Tabacco announces that it is investigating potential securities law violations by Compass Diversified Holdings (“Compass” or the “Company”) (NYSE: CODI). About the Investigation On May 7, 2025, after …

AD Retail Media Expands Off-Site Advertising Solutions Through Partnership with Chicory

AD Retail Media Expands Off-Site Advertising Solutions Through Partnership with Chicory

SALISBURY, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- AD Retail Media, the retail media arm of the East Coast's largest grocery retail group, Ahold Delhaize USA, today announced a strategic partnership with Chicory to offer enhanced off-site advertising …

Tier One Partners Expands Client Roster With Wins in Healthcare Technology and Business Transformation

Tier One Partners Expands Client Roster With Wins in Healthcare Technology and Business Transformation

BOSTON and CHICAGO, May 08, 2025 (GLOBE NEWSWIRE) -- Tier One Partners, an award-winning integrated marketing agency, today announced the addition of two new B2B brands to its client roster: Reveleer and Oliver Wight. These partnerships further demonstrate …

Occupancy Analytics Leader Lambent Adds Two Higher Ed Veterans to its Board of Advisors

Occupancy Analytics Leader Lambent Adds Two Higher Ed Veterans to its Board of Advisors

BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Occupancy analytics software company Lambent today announced the addition of two new members to its Board of Advisors. Robert Wynkoop, Vice President of Operations and Finance at Covenant College, and Maria O' …

Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, based on currently available clinical data from its key clinical programs and a challenging fundraising …

Lifeward Completes Research Program with Israeli Human-Robot Interaction Consortium to Integrate Artificial Intelligence and Exoskeletons

Lifeward Completes Research Program with Israeli Human-Robot Interaction Consortium to Integrate Artificial Intelligence and Exoskeletons

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or …

Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update

Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update

Tovecimig (DLL4 x VEGF-A bispecific antibody) met the primary endpoint in the ongoing randomized Phase 2/3 Study in patients with biliary tract cancer (BTC). Achieved a 17.1% overall response rate (ORR), including one complete response, compared to a 5.3% …

Corbus Pharmaceuticals to Present at the 2025 RBC Capital Markets Global Healthcare Conference

Corbus Pharmaceuticals to Present at the 2025 RBC Capital Markets Global Healthcare Conference

Norwood, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on- …

Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates

Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates

-- Initial data from Phase 1/2 trial of PM359 for p47phox CGD expected in 2025 -- -- IND and/or CTA for PM577 for Wilson’s Disease on-track for 1H 2026 -- -- Unveiled potentially best-in-class program for AATD; IND and/or CTA filing targeted for mid-2026 …

Cue Biopharma to Host Virtual Investor Event on May 15, 2025

Cue Biopharma to Host Virtual Investor Event on May 15, 2025

Mobilizing the Immune System: Cue Biopharma's Novel Biologics Portfolio Event Virtual Event will Feature Key Opinion Leaders Richard DiPaolo, PhD, and Andrew Cope, MD, PhD BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a …

Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance

Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance

Record First Quarter MACI Revenue of $46.3 Million and First Quarter Total Revenue of $52.6 Million Approximately 400 MACI Arthro Surgeons Trained to Date, with Year-to-Date Biopsy Growth Over 30% for Trained Surgeons Second Quarter Total Revenue and MACI …

Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress

Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress

On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of 2025 Dosed first patient in the global Phase 3 MAGNITUDE-2 study evaluating nexiguran ziclumeran (nex-z) in patients with hereditary …

MACOM Reports Fiscal Second Quarter 2025 Financial Results

MACOM Reports Fiscal Second Quarter 2025 Financial Results

LOWELL, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- MACOM Technology Solutions Holdings, Inc. (“MACOM”) (Nasdaq: MTSI), a leading supplier of semiconductor products, today announced its financial results for its fiscal second quarter ended April 4, 2025. …

Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

- FDA (CDER) Type C meeting held in May 2025 for DYNE-101 in DM1 and Dyne plans to provide a regulatory update following receipt of meeting minutes - - Registrational Expansion Cohort of ACHIEVE Trial of DYNE-101 in DM1 initiated to support potential …

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results

Updated Phase 2 data to be presented at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, in combination with atezolizumab in patients with metastatic microsatellite stable colorectal cancer (MSS CRC) Advancing multiple masked T cell …

Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update

Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update

Dosing complete in the first two cohorts of INLIGHT trial in obesity of WVE-007 (INHBE siRNA), designed to induce healthy weight loss by reducing fat without impacting muscle; clinical data on track for 2H 2025 Dosing underway in second single dose cohort …

Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

WALTHAM, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, May 15, …

HilleVax Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress

HilleVax Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress

$159.5 million of cash, cash equivalents and marketable securities as of March 31, 2025 The company is exploring the potential for continued development of its norovirus vaccine candidates in adults as well as business development related activities and …

Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates

Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates

VAV1-directed MRT-6160 program advancing toward multiple Phase 2 studies, enabled by Phase 1 SAD/MAD study data supporting broad potential application in immune-mediated diseases MRT-2359 Phase 1/2 study data demonstrate encouraging signals of clinical …

Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

– WTX-124 Phase 1/1b clinical trial on track for data readouts and interactions with the FDA in the second half of the year – – First patient dosed in the Phase 1b/2 clinical trial of WTX-330, seeking to build on the clinical activity and tolerability …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service